BNT164b1
TB/FLU-05E
TB/FLU-05E is a mucosal TB vaccine candidate based on recombinant attenuated influenza vector (Flu/THSP) co-expressing truncated NS1 protein NS1(1–124) and a full-length TB10.4 and HspX proteins of M.tb within an NS1 protein open reading frame. Vaccine formulation: Liquid nasal spray.
Read MoreBCG (Revaccination)*
The Gates MRI BCG ReVax trial is a Phase 2B trial conducted to inform policy. No label change or new indication is intended. The trial compares AJVaccines’ BCG (Danish 1331) to saline placebo for the prevention of sustained IGRA conversion (initial conversion and IGRA-positive 3 and 6 months post initial conversion), as a proxi for…
Read MoreM72/AS01E
The M72/AS01E vaccine candidate consists of the M72 fusion protein and the proprietary GSK adjuvant system AS01E.
Read MoreMTBVAC
MTBVAC is an attenuated M. tuberculosis strain, by genetically engineering two independent unmarked stable deletion mutations in the virulence genes phoP and fadD26, based on clinical strain of the Euro-American lineage 4, the most widespread transmitted lineage between humans. MTBVAC includes RD1 absent in BCG, which contains 23% of the known human T-cell epitopes present…
Read More